TOVX · XBRL financial data
Theriva Biologics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TOVX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 5,131 | 7,800 | 11,723 | 14,311 | 12,031 | 8,604 |
| General and administrative | 5,029 | 6,474 | 9,858 | 7,120 | 7,396 | 15,447 |
| Total operating expenses | 10,160 | 14,274 | 21,581 | 21,431 | 26,346 | 24,051 |
| Operating income (loss) | (10,160) | (14,274) | (21,581) | (21,431) | (26,346) | (24,051) |
| Interest income | 44 | 6 | 512 | 1,439 | 697 | 287 |
| Interest expense | — | — | — | — | 6 | 61 |
| Income tax expense (benefit) | 0 | 0 | (1,425) | (1,640) | 0 | — |
| Net income (loss) | (10,043) | (14,267) | (19,685) | (18,349) | — | — |
| Earnings per share, basic‡ USD per share | (1,650.00) | (475.00) | (32.75) | (28.50) | (19.03) | (2.08) |
| Earnings per share, diluted‡ USD per share | (1,650.00) | (475.00) | (32.75) | (28.50) | (19.03) | (2.08) |
| Weighted average shares, basic‡ thousands of shares | 8 | 49 | 613 | 644 | 1,348 | 12,141 |
| Weighted average shares, diluted‡ thousands of shares | 8 | 49 | 613 | 644 | 1,348 | 12,141 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (TOVX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6,227 | 67,325 | 41,786 | 23,177 | 11,609 | 13,056 |
| Prepaid and other current assets | 1,707 | 1,533 | 3,734 | 2,414 | 1,444 | 1,060 |
| Total current assets | 7,934 | 68,858 | 45,520 | 27,403 | 16,281 | 17,467 |
| Property and equipment, net | 174 | 101 | 345 | 422 | 270 | 222 |
| Right-of-use asset | 279 | 1,383 | 1,199 | 1,759 | 1,272 | 803 |
| Goodwill | — | 0 | 5,525 | 5,700 | 0 | — |
| Total assets | 8,410 | 70,365 | 71,861 | 55,219 | 35,352 | 38,239 |
| Accounts payable | 886 | 524 | 915 | 770 | 859 | 1,014 |
| Accrued liabilities | 925 | 1,928 | 1,496 | 2,995 | 3,368 | 6,276 |
| Total current liabilities | 2,966 | 3,554 | 7,060 | 6,738 | 7,585 | 10,014 |
| Lease liability, non-current | 186 | 1,403 | 1,187 | 1,442 | 873 | 352 |
| Total liabilities | 3,152 | 4,957 | 17,297 | 15,522 | 16,285 | 22,856 |
| Accumulated deficit | (248,094) | (271,284) | (290,969) | (309,318) | (334,971) | (358,710) |
| Total stockholders' equity | (4,767) | 65,408 | — | — | — | — |
| Total liabilities and equity | 8,410 | 70,365 | 71,861 | 55,219 | 35,352 | 38,239 |
| Common shares outstanding (cover page)‡ thousands of shares | 52 | 63 | 605 | 686 | 2,782 | 45,893 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (August 2024); filings made before it reported them unadjusted.
- † Share count changed about 4x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (TOVX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (10,043) | (14,267) | (19,685) | (18,349) | — | — |
| Stock-based compensation | 350 | 416 | 475 | 552 | 671 | 654 |
| Depreciation and amortization | 201 | 87 | 85 | 135 | 137 | 108 |
| Net cash from operating activities | (12,168) | (12,890) | (19,082) | (18,996) | (16,937) | (16,669) |
| Purchases of property and equipment | 9 | 14 | 116 | 202 | 1 | 35 |
| Net cash from investing activities | (9) | (14) | (4,396) | (202) | (1) | (35) |
| Proceeds from issuing common stock | 3,359 | 65,960 | 0 | — | — | — |
| Proceeds from issuing equity | 3,359 | — | — | — | — | — |
| Proceeds from long-term debt | — | — | — | — | — | 1,507 |
| Repayments of long-term debt | — | 0 | 1,376 | 75 | 67 | — |
| Net cash from financing activities | 3,359 | 74,002 | (1,930) | 625 | 5,496 | 18,193 |
| Net change in cash | — | 61,098 | (25,408) | (18,606) | (11,574) | 1,397 |
- † Share count changed about 4x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Theriva Biologics | 11,337 | 0* | (3,085)* | 45.9M | 3.7 quarters | 10-QJun 30, 2026 |
| Jaguar Health | 3,788 | 1,225 | (5,338)* | not reported | 0.7 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| China Pharma Holdings | 305 | 948 | (33)* | 43.0M | 9.3 quarters | 10-QJun 30, 2026 |
| Synlogic | 13,183 | 0 | (922)* | 12.2M | 14.3 quarters | 10-QJun 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.